Therapeutically, restoring mitochondrial fitness in exhausted T cells (via metabolic reprogramming, enhancing mitobiogenesis/PGC-1α, or reducing deleterious mtROS) and targeting tumor mitochondrial adaptations are promising strategies to overcome checkpoint resistance and reinvigorate anti-tumor immunity (260). Here, PPARGC1A is linked to neoplasm.